Provectus Biopharmaceuticals Announces Acceptance of PV-10® Systemic Administration Abstract at American Association for Cancer Research (AACR) Annual Meeting 2022

<p>KNOXVILLE, TN, Feb. 08, 2022 (GLOBE NEWSWIRE) — Provectus (OTCQB: PVCT) today announced that preclinical research on systemic administration of investigational cancer immunotherapy PV-10 (rose bengal sodium) for the treatment of high-risk and refractory adult solid tumor cancers will be presented at the annual meeting of the American Association for Cancer Research (AACR), to be …</p>
<p>The post <a rel="nofollow" href="https://forextv.com/top-news/provectus-biopharmaceuticals-announces-acceptance-of-pv-10-systemic-administration-abstract-at-american-association-for-cancer-research-aacr-annual-meeting-2022/">Provectus Biopharmaceuticals Announces Acceptance of PV-10® Systemic Administration Abstract at American Association for Cancer Research (AACR) Annual Meeting 2022</a> appeared first on <a rel="nofollow" href="https://forextv.com">ForexTV</a>.</p>